Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26924598 | 0.98 | TSHR (0.47) | TSHRLMNACHRM2CHRM4CHRM5 | |
| SCHEMBL28515744 | 0.98 | TSHR (0.47) | TSHRLMNACHRM2CHRM4CHRM5 | |
| SCHEMBL28715308 | 0.88 | TSHR (0.52) | TSHRLMNACHRM2CHRM4CHRM5 | |
| SCHEMBL28715324 | 0.88 | TSHR (0.55) | TSHRLMNACHRM2CHRM4CHRM5 | |
| SCHEMBL27166334 | 0.88 | TSHR (0.55) | TSHRLMNACHRM2CHRM4CHRM5 | |
| SCHEMBL4341911 | 0.80 | TSHR (0.55) | TSHRNPC1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL868739 | 0.79 | — | — | |
| SCHEMBL25376031 | 0.78 | TSHR (0.48) | TSHRNPC1GSTP1HSD17B10ALDH1A1 | |
| SCHEMBL1716036 | 0.78 | ALDH1A1 (0.56) | TSHRLMNACHRM2CHRM4CHRM5 | |
| SCHEMBL30552236 | 0.78 | TSHR (0.50) | TSHRLMNACHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116783205-A | Compounds for degradation of cyclin-dependent kinase 2 via the ubiquitin proteasome pathway | 尼坎治疗公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-109415336-B | MDM2 protein degradation agent | 密执安大学评议会 | 2023-08-29 | — | — | CN | disclosed |
| CN-114245798-A | CGRP antagonist compounds | 赫普泰雅治疗有限公司 | 2022-03-25 | — | — | CN | disclosed |
| CN-113788818-A | MDM2 protein degrading agent | 密执安大学评议会 | 2021-12-14 | — | — | CN | disclosed |
| CN-109311890-B | BET protein degradation agent | 密执安大学评议会 | 2021-08-31 | — | — | CN | disclosed |
| CN-112105385-A | IRAK degrading agents and uses thereof | 凯麦拉医疗公司 | 2020-12-18 | — | — | CN | disclosed |
| US-20140079632-A1 | ACTIVITY-BASED PROBES FOR THE UROKINASE PLASMINOGEN ACTIVATOR | UNIVERSITEIT ANTWERPEN (BE) | 2014-03-20 | — | — | US | disclosed |
| US-20140079632-A1 | ACTIVITY-BASED PROBES FOR THE UROKINASE PLASMINOGEN ACTIVATOR | UNIVERSITEIT ANTWERPEN (BE) | 2014-03-20 | — | — | US | disclosed |
| US-20140079632-A1 | ACTIVITY-BASED PROBES FOR THE UROKINASE PLASMINOGEN ACTIVATOR | UNIVERSITEIT ANTWERPEN (BE) | 2014-03-20 | — | — | US | disclosed |
| EP-2707034-A1 | ACTIVITY-BASED PROBES FOR THE UROKINASE PLASMINOGEN ACTIVATOR | Universiteit Antwerpen (BE) | 2014-03-19 | — | — | EP | disclosed |
| WO-2012152807-A1 | ACTIVITY-BASED PROBES FOR THE UROKINASE PLASMINOGEN ACTIVATOR | UNIVERSITEIT ANTWERPEN (BE) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140079632-A1 | ACTIVITY-BASED PROBES FOR THE UROKINASE PLASMINOGEN ACTIVATOR | PLAU, SERPINE1, PRSS3 | TSHR 1872/4885LMNA 1423/4885CHRM2 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.